Verastem Announces Positive RAMP 205 Trial Results

Verastem ( (VSTM) ) has provided an announcement.

On May 22, 2025, Verastem held its annual stockholders meeting in Needham, Massachusetts, where key proposals were voted on, including the election of Class I directors and the ratification of Ernst & Young LLP as the independent accounting firm. Concurrently, Verastem announced positive results from the RAMP 205 trial, showing an 83% overall response rate in the dose level 1 cohort for metastatic pancreatic cancer treatment. This success has led to plans for a Phase 3 trial in 2026, indicating a significant step forward in their clinical development and potential market expansion.

The most recent analyst rating on (VSTM) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Verastem stock, see the VSTM Stock Forecast page.

Spark’s Take on VSTM Stock

According to Spark, TipRanks’ AI Analyst, VSTM is a Neutral.

Verastem’s overall stock score is primarily impacted by its weak financial performance, characterized by ongoing losses and negative equity. However, positive technical indicators and recent corporate events, such as the $75M private placement, provide some optimism for future growth. Valuation remains constrained by negative earnings, but strategic initiatives and product development efforts could drive improvements. The stock represents a speculative opportunity, with potential upside if financial health and operational efficiencies improve.

To see Spark’s full report on VSTM stock, click here.

More about Verastem

Verastem Oncology is a biopharmaceutical company focused on developing new medicines for patients with RAS/MAPK pathway-driven cancers. Their primary products include avutometinib and defactinib, which are being evaluated for various cancer treatments, including metastatic pancreatic ductal adenocarcinoma and KRAS-mutated recurrent low-grade serous ovarian cancer.

Average Trading Volume: 1,231,390

Technical Sentiment Signal: Buy

Current Market Cap: $411M

For a thorough assessment of VSTM stock, go to TipRanks’ Stock Analysis page.